Cargando…

Tocilizumab (TCZ) Decreases Angiogenesis in Rheumatoid Arthritis Through Its Regulatory Effect on miR-146a-5p and EMMPRIN/CD147

BACKGROUND: Angiogenesis is a major contributor to the development of inflammation during Rheumatoid arthritis (RA), as the vascularization of the pannus provides nutrients and oxygen for the infiltrating immune cells and proliferating synoviocytes. Tocilizumab (TCZ) is an anti-IL-6 receptor antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Zisman, Devy, Safieh, Mirna, Simanovich, Elina, Feld, Joy, Kinarty, Amalia, Zisman, Liron, Gazitt, Tal, Haddad, Amir, Elias, Muna, Rosner, Itzhak, Kaly, Lisa, Rahat, Michal A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714881/
https://www.ncbi.nlm.nih.gov/pubmed/34975837
http://dx.doi.org/10.3389/fimmu.2021.739592
_version_ 1784624023510974464
author Zisman, Devy
Safieh, Mirna
Simanovich, Elina
Feld, Joy
Kinarty, Amalia
Zisman, Liron
Gazitt, Tal
Haddad, Amir
Elias, Muna
Rosner, Itzhak
Kaly, Lisa
Rahat, Michal A.
author_facet Zisman, Devy
Safieh, Mirna
Simanovich, Elina
Feld, Joy
Kinarty, Amalia
Zisman, Liron
Gazitt, Tal
Haddad, Amir
Elias, Muna
Rosner, Itzhak
Kaly, Lisa
Rahat, Michal A.
author_sort Zisman, Devy
collection PubMed
description BACKGROUND: Angiogenesis is a major contributor to the development of inflammation during Rheumatoid arthritis (RA), as the vascularization of the pannus provides nutrients and oxygen for the infiltrating immune cells and proliferating synoviocytes. Tocilizumab (TCZ) is an anti-IL-6 receptor antibody that is used in the treatment of RA patients, and has been shown to exert anti-inflammatory effects. However, its effects on angiogenesis are not fully elucidated, and the molecular mechanisms regulating this effect are unknown. METHODS: We evaluated the concentrations of several pro- and anti-angiogenic factors and the expression levels of several microRNA molecules that are associated with RA and angiogenesis in serum samples obtained from 40 RA patients, before and 4 months after the initiation of TCZ treatment. Additionally, we used an in vitro co-culture system of fibroblasts (the HT1080 cell line) and monocytes (the U937 cell line) to explore the mechanisms of TCZ action. RESULTS: Serum samples from RA patients treated with TCZ exhibited reduced circulating levels of EMMPRIN/CD147, enhanced expression of circulating miR-146a-5p and miR-150-5p, and reduced the angiogenic potential as was manifested by the lower number of tube-like structures that were formed by EaHy926 endothelial cell line. In vitro, the accumulation in the supernatants of the pro-angiogenic factors EMMPRIN, VEGF and MMP-9 was increased by co-culturing the HT1080 fibroblasts and the U937 monocytes, while the accumulation of the anti-angiogenic factor thrombospondin-1 (Tsp-1) and the expression levels of miR-146a-5p were reduced. Transfection of HT1080 cells with the miR-146a-5p mimic, decreased the accumulation of EMMPRIN, VEGF and MMP-9. When we neutralized EMMPRIN with a blocking antibody, the supernatants derived from these co-cultures displayed reduced migration, proliferation and tube formation in the functional assays. CONCLUSIONS: Our findings implicate miR-146a-5p in the regulation of EMMPRIN and propose that TCZ affects angiogenesis through its effects on EMMPRIN and miR-146a-5p.
format Online
Article
Text
id pubmed-8714881
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87148812021-12-30 Tocilizumab (TCZ) Decreases Angiogenesis in Rheumatoid Arthritis Through Its Regulatory Effect on miR-146a-5p and EMMPRIN/CD147 Zisman, Devy Safieh, Mirna Simanovich, Elina Feld, Joy Kinarty, Amalia Zisman, Liron Gazitt, Tal Haddad, Amir Elias, Muna Rosner, Itzhak Kaly, Lisa Rahat, Michal A. Front Immunol Immunology BACKGROUND: Angiogenesis is a major contributor to the development of inflammation during Rheumatoid arthritis (RA), as the vascularization of the pannus provides nutrients and oxygen for the infiltrating immune cells and proliferating synoviocytes. Tocilizumab (TCZ) is an anti-IL-6 receptor antibody that is used in the treatment of RA patients, and has been shown to exert anti-inflammatory effects. However, its effects on angiogenesis are not fully elucidated, and the molecular mechanisms regulating this effect are unknown. METHODS: We evaluated the concentrations of several pro- and anti-angiogenic factors and the expression levels of several microRNA molecules that are associated with RA and angiogenesis in serum samples obtained from 40 RA patients, before and 4 months after the initiation of TCZ treatment. Additionally, we used an in vitro co-culture system of fibroblasts (the HT1080 cell line) and monocytes (the U937 cell line) to explore the mechanisms of TCZ action. RESULTS: Serum samples from RA patients treated with TCZ exhibited reduced circulating levels of EMMPRIN/CD147, enhanced expression of circulating miR-146a-5p and miR-150-5p, and reduced the angiogenic potential as was manifested by the lower number of tube-like structures that were formed by EaHy926 endothelial cell line. In vitro, the accumulation in the supernatants of the pro-angiogenic factors EMMPRIN, VEGF and MMP-9 was increased by co-culturing the HT1080 fibroblasts and the U937 monocytes, while the accumulation of the anti-angiogenic factor thrombospondin-1 (Tsp-1) and the expression levels of miR-146a-5p were reduced. Transfection of HT1080 cells with the miR-146a-5p mimic, decreased the accumulation of EMMPRIN, VEGF and MMP-9. When we neutralized EMMPRIN with a blocking antibody, the supernatants derived from these co-cultures displayed reduced migration, proliferation and tube formation in the functional assays. CONCLUSIONS: Our findings implicate miR-146a-5p in the regulation of EMMPRIN and propose that TCZ affects angiogenesis through its effects on EMMPRIN and miR-146a-5p. Frontiers Media S.A. 2021-12-15 /pmc/articles/PMC8714881/ /pubmed/34975837 http://dx.doi.org/10.3389/fimmu.2021.739592 Text en Copyright © 2021 Zisman, Safieh, Simanovich, Feld, Kinarty, Zisman, Gazitt, Haddad, Elias, Rosner, Kaly and Rahat https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zisman, Devy
Safieh, Mirna
Simanovich, Elina
Feld, Joy
Kinarty, Amalia
Zisman, Liron
Gazitt, Tal
Haddad, Amir
Elias, Muna
Rosner, Itzhak
Kaly, Lisa
Rahat, Michal A.
Tocilizumab (TCZ) Decreases Angiogenesis in Rheumatoid Arthritis Through Its Regulatory Effect on miR-146a-5p and EMMPRIN/CD147
title Tocilizumab (TCZ) Decreases Angiogenesis in Rheumatoid Arthritis Through Its Regulatory Effect on miR-146a-5p and EMMPRIN/CD147
title_full Tocilizumab (TCZ) Decreases Angiogenesis in Rheumatoid Arthritis Through Its Regulatory Effect on miR-146a-5p and EMMPRIN/CD147
title_fullStr Tocilizumab (TCZ) Decreases Angiogenesis in Rheumatoid Arthritis Through Its Regulatory Effect on miR-146a-5p and EMMPRIN/CD147
title_full_unstemmed Tocilizumab (TCZ) Decreases Angiogenesis in Rheumatoid Arthritis Through Its Regulatory Effect on miR-146a-5p and EMMPRIN/CD147
title_short Tocilizumab (TCZ) Decreases Angiogenesis in Rheumatoid Arthritis Through Its Regulatory Effect on miR-146a-5p and EMMPRIN/CD147
title_sort tocilizumab (tcz) decreases angiogenesis in rheumatoid arthritis through its regulatory effect on mir-146a-5p and emmprin/cd147
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714881/
https://www.ncbi.nlm.nih.gov/pubmed/34975837
http://dx.doi.org/10.3389/fimmu.2021.739592
work_keys_str_mv AT zismandevy tocilizumabtczdecreasesangiogenesisinrheumatoidarthritisthroughitsregulatoryeffectonmir146a5pandemmprincd147
AT safiehmirna tocilizumabtczdecreasesangiogenesisinrheumatoidarthritisthroughitsregulatoryeffectonmir146a5pandemmprincd147
AT simanovichelina tocilizumabtczdecreasesangiogenesisinrheumatoidarthritisthroughitsregulatoryeffectonmir146a5pandemmprincd147
AT feldjoy tocilizumabtczdecreasesangiogenesisinrheumatoidarthritisthroughitsregulatoryeffectonmir146a5pandemmprincd147
AT kinartyamalia tocilizumabtczdecreasesangiogenesisinrheumatoidarthritisthroughitsregulatoryeffectonmir146a5pandemmprincd147
AT zismanliron tocilizumabtczdecreasesangiogenesisinrheumatoidarthritisthroughitsregulatoryeffectonmir146a5pandemmprincd147
AT gazitttal tocilizumabtczdecreasesangiogenesisinrheumatoidarthritisthroughitsregulatoryeffectonmir146a5pandemmprincd147
AT haddadamir tocilizumabtczdecreasesangiogenesisinrheumatoidarthritisthroughitsregulatoryeffectonmir146a5pandemmprincd147
AT eliasmuna tocilizumabtczdecreasesangiogenesisinrheumatoidarthritisthroughitsregulatoryeffectonmir146a5pandemmprincd147
AT rosneritzhak tocilizumabtczdecreasesangiogenesisinrheumatoidarthritisthroughitsregulatoryeffectonmir146a5pandemmprincd147
AT kalylisa tocilizumabtczdecreasesangiogenesisinrheumatoidarthritisthroughitsregulatoryeffectonmir146a5pandemmprincd147
AT rahatmichala tocilizumabtczdecreasesangiogenesisinrheumatoidarthritisthroughitsregulatoryeffectonmir146a5pandemmprincd147